Health

Japan Ground Self-Defense Force Adopts MEDIROM MOTHER Labs REMONY for Advanced Health Monitoring and Heatstroke Safety

TOKYO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) today announced that its subsidiary, MEDIROM…

3 months ago

NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

September 18, 2025 16:30 ET  | Source: NovaBay Pharmaceuticals Inc. EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals,…

3 months ago

89bio, Inc. Announces Agreement to be Acquired by Roche

September 18, 2025 01:02 ET  | Source: 89bio, Inc. – 89bio stockholders to receive up to $20.50 per share in…

3 months ago

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most…

3 months ago

Science Based Targets initiative (SBTi) validates EUROAPIs near-term climate targets

42% reduction in Scope 1 and 2 Greenhouse Gas emissions by 2030 (vs. 2022)25% reduction in Scope 3 GHG emissions…

3 months ago

Arcutis To Present Multiple New ZORYVE (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin…

3 months ago

ALK and GenSci partner to expand the AIT market in China

Inside Information GenSci is granted exclusive rights to ALK’s house dust mite AIT products in China. ALK will be eligible…

3 months ago

Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease

MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative…

3 months ago

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company…

3 months ago

AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th

PHOENIX and LONDON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated…

3 months ago